Net revenue of $15.9 million in the first quarter of 2022, a 125% increase compared to the first quarter of 2021
Received FDA pre-market approval (PMA) of OCS™ DCD heart indication on April 28, 2022
Results from the U.S. randomized OCS™ DCD Heart trial along with OCS™ Lung Trial 5-year data presented at the International Society of Heart and Lung Transplantation (ISHLT) annual meeting
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.